Oscar Gershanik, MD, Favaloro University, Buenos Aires, Argentina, discusses the current landscape of clinical trials for disease-modifying treatments for Parkinson’s disease (PD). Approximately 63 different molecules are under investigation, targeting various mechanisms such as immunological pathways, inflammation, oxidation, and trophic mechanisms. Some of these drugs aim to modify the disease by targeting the alpha-synuclein protein involved in PD pathogenesis. However, despite promising avenues of research, no treatment has yet reached a stage where it can be confidently declared as disease-modifying. Prof. Gershanik remains hopeful that advancements in PD treatment will be made in the future. This interview took place at the 2023 International Congress of Parkinson’s Disease and Movement Disorders in Copenhagen, Denmark.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
